Starton Therapeutics
Dr. Anderson is Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute. He has over four decades of experience researching multiple myeloma in both laboratory and clinical settings. Dr. Anderson is the recipient of several awards including the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award; the American Association for Cancer Research Joseph H. Burchenal Award, the American Society of Hematology William Dameshek Prize, and the American Society of Clinical Oncology David A. Karnofsky Award. He is a member of the Institute of Medicine of the National Academy of Sciences, and has served as President of the International Myeloma Society and the American Society of Hematology.
This person is not in the org chart
This person is not in any offices
Starton Therapeutics
Starton Therapeutics is a clinical-stage biotechnology company that is transforming standard-of-care therapies with proprietary transdermal technology, so people with cancer can receive continuous treatment to live better, longer.